Meloxicam SBEβCD Inclusion Complex for Rapid Absorption
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Meloxicam, a nonsteroidal anti-inflammatory drug, has poor aqueous solubility, leading to reduced bioavailability and delayed pain relief, which can be addressed by forming an inclusion complex with cyclodextrins like sulfobutyl ether β-cyclodextrin (SBEβCD) and administering it with a bicarbonate to enhance solubility and absorption.
Innovation Solution
The formation of an inclusion complex of meloxicam with SBEβCD and a bicarbonate, such as sodium bicarbonate, facilitates increased bioavailability and rapid absorption of meloxicam, when administered orally or intravenously, often in combination with rizatriptan for treating migraine and pain conditions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If meloxicam is administered in its conventional form, then the drug can be given orally, but its poor aqueous solubility reduces bioavailability and delays pain relief
Solution Approach 1:
Cyclodextrins are used as intermediary carriers to complex with meloxicam, forming water-soluble inclusion complexes that enhance bioavailability while maintaining the original meloxicam molecule's pharmacological properties
Solution Approach 2:
The solubility parameter of meloxicam is changed by forming inclusion complexes with cyclodextrins, transforming it from poorly soluble to highly water-soluble form for improved absorption
2Reliability
If the dosage form includes multiple components (meloxicam complex, bicarbonate, rizatriptan), then treatment efficacy is improved, but the device complexity increases
Solution Approach 1:
Multiple therapeutic agents (meloxicam complex, bicarbonate, rizatriptan) are merged into a single oral dosage form, providing combined anti-inflammatory, analgesic, and migraine-specific treatment in one administration
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach significantly enhances the bioavailability and absorption of meloxicam, providing rapid and sustained pain relief, reducing the need for rescue medication and improving treatment outcomes in patients with a history of inadequate responses to prior treatments.
Implementation Method 1
In aqueous solutions, cyclodextrins can form complexes (i.e., an inclusion complex) with drugs by incorporating the drug into the center/hydrophobic portion of the cyclodextrin ring
Implementation Method 2
Disclosed herein are formulations for an inclusion complex of cyclodextrin and meloxicam with bicarbonate and methods of use thereof
Data Source
AI summary
Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.